Showing 2611-2620 of 3039 results for "".
- Adverum Biotechnologies Announces New GMP Gene Therapy Manufacturing Facilityhttps://modernod.com/news/adverum-biotechnologies-announces-new-gmp-gene-therapy-manufacturing-facility/2478734/Adverum Biotechnologies announced plans for a new Good Manufacturing Practices facility in Durham, North Carolina. Adverum will invest over $80 million in the 174,000-square-foot facility, located in Research Triangle Park (RTP). The site will include four 1,000-liter bioreactors, with space for
- Kala Pharmaceuticals Announces Commercial Availability of Eysuvis for the Treatment of Dry Eye Diseasehttps://modernod.com/news/kala-pharmaceuticals-announces-commercial-availability-of-eysuvis-for-the-treatment-of-dry-eye-disease/2478729/Kala Pharmaceuticals announced the launch of Eysuvis (loteprednol etabonate ophthalmic suspension) 0.25% for the short-term (up to 2 weeks) treatment of the signs and symptoms of dry eye disease. Eysuvis is now available in national and
- IACTA Pharmaceuticals and Pharmaleads to Develop the World’s First Epithelial Protective Drug Harnessing Endogenous Analgesia for the Topical Treatment of Acute and Chronic Ocular Painhttps://modernod.com/news/iacta-pharmaceuticals-and-pharmaleads-to-develop-the-worlds-first-epithelial-protective-drug-harnessing-endogenous-analgesia-for-the-topical-treatment-of-acute-and-chronic-ocular-pain/2478730/IACTA Pharmaceuticals and Pharmaleads announced they have entered into licensing agreements with IACTA acquiring global rights to Pharmaleads’ Dual Enkephalinase Inhibitors (DENKI), a novel class of non-opioid compounds for the treatment of acute and chronic ocular pain. “With
- Alcon Commercially Launches AcrySof IQ Vivity Extended Depth of Focus IOL in UShttps://modernod.com/news/alcon-launches-acrysof-iq-vivity-extended-depth-of-focus-iol-in-us/2478731/Alcon has commercially launched the AcrySof IQ Vivity IOL, which the company describes as the first and only non-diffractive extended depth of focus IOL in the United States. Vivity is a first-of-its-kind, non-diffractive extended depth of focus IOL with Alcon’s proprietary non-diffractiv
- SIFI Launches Dry Eye Disease Device Synfohttps://modernod.com/news/sifi-launches-dry-eye-disease-synfo/2478726/SIFI announced the launch of Synfo, a novel medical device for dry eye disease. The new hypotonic formulation is a synergistic blend of two polymers—sodium hyaluronate and xanthan gum—and two osmoprotectants, betaine and glycine. In addition to moisturizing and lubricating, Synfo is design
- Birmingham Research Paves the Way for New Anti-Fibrotic Therapy for Glaucomahttps://modernod.com/news/birmingham-research-paves-the-way-for-new-anti-fibrotic-therapy-for-glaucoma/2478727/Scientists at the University of Birmingham, UK, have shown that a novel low molecular weight dextran-sulphate, ILB, could play a key role in treating open angle glaucoma (OAG). The research, reported in
- Sifi Launches Well Fusion Presbyopia Correcting Systemhttps://modernod.com/news/sifi-launches-well-fusion-presbyopia-correcting-system/2478688/SIFI announces the launch of the Well Fusion system and the Mini Well Proxa IOL, offering a novel solution that provides cataract patients the option to treat presbyopia with spectacle-free uninterrupted high-quality vision at all distances and in all lighting conditions. SIFI has develope
- EyeGate Pharma Announces Acquisition of Panoptes Pharmahttps://modernod.com/news/eyegate-pharma-announces-acquisition-of-panoptes-pharma/2478685/EyeGate Pharmaceuticals announced the acquisition of Panoptes Pharma, a privately-held clinical stage biotech company focused on developing a novel proprietary small molecule for the treatment of severe eye diseases with a high unmet medical need. EyeGate Pharmaceuticals will pay up to $4
- Demand, Pay for Travel ICU Nurses Soar as Hospitals Face Staff Crunch Due to COVID-19https://modernod.com/news/demand-pay-for-travel-icu-nurses-soar-as-hospitals-face-staff-crunch-due-to-covid-19/2478681/Staffing crunches caused by COVID-19 created a massive 305% increase in demand for intensive care unit travel nurses from March to November, according to a new report, as
- Envision Announces Dates, Calls for Submissions for 2021 Conferenceshttps://modernod.com/news/envision-announces-dates-calls-for-submissions-for-2021-conferences/2478668/Envision announced that it is now accepting submissions for clinical education and research presentations for its two 2021 conferences—events with the goal of closing practice gaps and disseminating the latest advancements in rehabilitation techniques, research and technology surrounding low visi